G. Yancey Gillespie, Ph.D.

Affiliations: 
Immunology, Surgery University of Alabama, Birmingham, Birmingham, AL, United States 
Area:
cytosine deaminase, UPRT, PNP; HSV that include TNFa, IL-2, IL-4, IL-5, IL-10, IL12, IL-16
Website:
http://www.uab.edu/medicine/immunology/faculty/100-gillespie
Google:
"G. Yancey Gillespie"
Bio:

https://www.uab.edu/medicine/neurosurgery/faculty/gillespie
https://scholar.google.com/citations?user=umoHkakAAAAJ&hl=en
https://www.worldcat.org/oclc/25665506

Mean distance: 106866
 

Parents

Sign in to add mentor
Julius Major Cruse grad student 1971 University of Mississippi (Cell Biology Tree)
 (Mediation and suppression of the primary alloimmune response in vitro: a model for immunologic enhancement)

Children

Sign in to add trainee
C. Ryan Miller post-doc 2000-2002 UAB
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Stackhouse CT, Anderson JC, Yue Z, et al. (2022) An in vivo model of glioblastoma radiation resistance identifies long non-coding RNAs and targetable kinases. Jci Insight
Boyd NH, Tran AN, Bernstock JD, et al. (2021) Glioma stem cells and their roles within the hypoxic tumor microenvironment. Theranostics. 11: 665-683
Chambers MR, Bentley RT, Crossman DK, et al. (2020) The One Health Consortium: Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Combination With a Checkpoint Inhibitor in Canine Patients With Sporadic High Grade Gliomas. Frontiers in Surgery. 7: 59
Bernstock JD, Vicario N, Rong L, et al. (2019) A novel in situ multiplex immunofluorescence panel for the assessment of tumor immunopathology and response to virotherapy in pediatric glioblastoma reveals a role for checkpoint protein inhibition. Oncoimmunology. 8: e1678921
Stackhouse CT, Rowland JR, Shevin RS, et al. (2019) A Novel Assay for Profiling GBM Cancer Model Heterogeneity and Drug Screening. Cells. 8
Totsch SK, Schlappi C, Kang KD, et al. (2019) Oncolytic herpes simplex virus immunotherapy for brain tumors: current pitfalls and emerging strategies to overcome therapeutic resistance. Oncogene
Sin-Chan P, Mumal I, Suwal T, et al. (2019) A C19MC-LIN28A-MYCN Oncogenic Circuit Driven by Hijacked Super-enhancers Is a Distinct Therapeutic Vulnerability in ETMRs: A Lethal Brain Tumor. Cancer Cell. 36: 51-67.e7
Bernstock JD, Vicario N, Li R, et al. (2019) Safety and efficacy of oncolytic HSV-1 G207 inoculated into the cerebellum of mice. Cancer Gene Therapy
Stackhouse C, Gillespie GY, Willey C. (2019) Dres-04. Long Non-Coding Rnas In Glioblastoma Tumor Recurrence And Therapy Resistance Neuro-Oncology. 21
Friedman GK, Bernstock JD, Chen D, et al. (2018) Enhanced Sensitivity of Patient-Derived Pediatric High-Grade Brain Tumor Xenografts to Oncolytic HSV-1 Virotherapy Correlates with Nectin-1 Expression. Scientific Reports. 8: 13930
See more...